Tirzepatide vs Semaglutide: 7 Key Differences Explained
Compare mechanisms, weight-loss research, side effects and UK prescribing considerations in this evidence-based guide.
View Comparison →Tirzepatide vs Semaglutide: Which Is Different and Why?
Tirzepatide vs semaglutide is one of the most important comparisons in modern incretin-based weight-management research.
Both compounds influence metabolic pathways involved in appetite, blood glucose regulation and body weight. However, they differ in receptor activity, clinical trial findings, licensed product formulations and individual prescribing considerations.
Tirzepatide is the active ingredient in Mounjaro, while semaglutide is the active ingredient in medicines including Wegovy and Ozempic. Their approved indications are not identical across every brand and formulation.
Tirzepatide vs Semaglutide Comparison Table
The following table compares the two active ingredients and representative licensed UK products.
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Receptor activity | GIP and GLP-1 | GLP-1 |
| UK brand examples | Mounjaro | Wegovy, Ozempic |
| Medicine class | Dual incretin receptor agonist | GLP-1 receptor agonist |
| Weight-management use | Licensed for eligible patients | Wegovy licensed for eligible patients |
| Weekly injection options | Yes | Yes |
| Oral formulations | No licensed oral tirzepatide product identified here | Licensed oral semaglutide formulations exist |
| Prescription required | Yes | Yes |
| Common side effects | Nausea, diarrhoea, vomiting, constipation | Nausea, diarrhoea, vomiting, constipation |
Note: Product indications and formulations can change. Always consult the specific licensed product information.
How Do Tirzepatide and Semaglutide Work?
Tirzepatide activates both GIP and GLP-1 receptors. These signalling pathways affect insulin secretion, appetite and metabolic regulation.
Semaglutide acts on the GLP-1 receptor. It influences glucose regulation, appetite and gastric emptying.
The difference in receptor activity helps explain why the two medicines can produce different average results in clinical trials.
Explore tirzepatide effects →
Tirzepatide vs Semaglutide Weight-Loss Results
The SURMOUNT-5 trial directly compared tirzepatide with semaglutide in adults with obesity but without type 2 diabetes. It included 751 randomised participants.
| Trial outcome | Tirzepatide | Semaglutide |
|---|---|---|
| Average weight change at week 72 | -20.2% | -13.7% |
| Average waist circumference change | -18.4 cm | -13.0 cm |
| Treatment period | 72 weeks | 72 weeks |
| Study population | Adults with obesity but without type 2 diabetes | |
In this particular study, tirzepatide produced a greater average reduction in body weight and waist circumference. Individual responses vary, and this result does not establish that one treatment is suitable for every patient.
Read the original SURMOUNT-5 study in The New England Journal of Medicine →
7 Key Differences Between Tirzepatide and Semaglutide
Receptor Targets
Tirzepatide acts on GIP and GLP-1 receptors. Semaglutide targets GLP-1 receptors.
Average Trial Outcomes
Tirzepatide produced greater mean weight reduction in the specific SURMOUNT-5 comparison.
Brand Names
Tirzepatide is marketed as Mounjaro. Semaglutide is used in products including Wegovy and Ozempic.
Available Formulations
Both have injectable options. Semaglutide also has licensed oral formulations.
Side-Effect Profiles
Both commonly cause gastrointestinal symptoms. The frequency and severity vary by treatment, dose and individual.
Licensed Indications
Indications depend on the specific medicine and formulation. Not every semaglutide product has the same approved uses.
Individual Suitability
Clinical history, contraindications, other medicines and treatment goals influence prescribing decisions.

Side Effects and Important Safety Differences
Both medicines can cause nausea, vomiting, diarrhoea, constipation and abdominal discomfort.
More serious adverse reactions are possible. Prescribers consider medical history, other treatments, relevant contraindications and monitoring requirements.
Neither medicine should be selected solely on the basis of a comparison chart or average trial outcome.
Tirzepatide vs Semaglutide in the UK
UK readers commonly encounter tirzepatide under the Mounjaro brand and semaglutide under brands such as Wegovy and Ozempic. Both are prescription-only medicines.
Approved uses, clinical eligibility, available formulations and prescribing conditions must be checked against the relevant product documentation.
For additional educational reading, explore our Tirzepatide UK guide and tirzepatide effects article .
Tirzepatide vs Semaglutide FAQs
Is tirzepatide more effective than semaglutide for weight loss?
In SURMOUNT-5, tirzepatide produced greater average weight loss than semaglutide over 72 weeks. This finding applies to the trial population and treatment regimens studied; individual results vary.
What is the main difference between tirzepatide and semaglutide?
Tirzepatide activates both GIP and GLP-1 receptors, whereas semaglutide acts on GLP-1 receptors.
Is Mounjaro tirzepatide or semaglutide?
Mounjaro contains tirzepatide. Wegovy and Ozempic contain semaglutide.
Do tirzepatide and semaglutide have similar side effects?
Both commonly cause gastrointestinal adverse effects, including nausea, diarrhoea and vomiting. Their complete safety information should be reviewed separately.
Are both medicines available in the UK?
Licensed tirzepatide and semaglutide medicines are available in the UK for specified indications, subject to prescribing requirements and availability.
Can tirzepatide and semaglutide be used together?
They should not be combined on personal initiative. Any change between therapies requires assessment by a qualified prescriber.
Does the SURMOUNT-5 trial prove tirzepatide is best for everyone?
No. It demonstrated greater mean weight reduction in a defined study population. Treatment suitability depends on many clinical factors.
Scientific References and Product Information
1. SURMOUNT-5 clinical trial: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity . New England Journal of Medicine, 2025.
2. Mounjaro product information: Eli Lilly Mounjaro Summary of Product Characteristics .
3. Wegovy product information: Novo Nordisk Wegovy Summary of Product Characteristics .
Continue Exploring GLP-1 Research
Discover further educational articles about tirzepatide, receptor mechanisms, clinical studies and UK medicine information.
Explore Tirzepatide UK →

Pingback: Can Tirzepatide UK Be Trusted | Millions Of Testimonies